Providing Access to Unlicensed Medicines

Deprecated: Function get_magic_quotes_gpc() is deprecated in C:\home\site\wwwroot\wp-content\plugins\admin-menu-editor-pro\includes\menu-editor-core.php on line 3454

Notice: Trying to access array offset on value of type null in C:\home\site\wwwroot\wp-content\plugins\autoptimize\classes\autoptimizeImages.php on line 178

Deprecated: Function get_magic_quotes_gpc() is deprecated in C:\home\site\wwwroot\wp-content\plugins\wp-toolbar-editor\Abe\AdminBarEditor.php on line 50

Warning: Creating default object from empty value in C:\home\site\wwwroot\wp-content\themes\inceptua\nectar\redux-framework\ReduxCore\inc\class.redux_filesystem.php on line 29

Notice: Trying to access array offset on value of type bool in C:\home\site\wwwroot\wp-content\plugins\wp-super-cache\wp-cache.php on line 3716
Providing Access to Unlicensed Medicines - Inceptua Group

Notice: Trying to access array offset on value of type bool in C:\home\site\wwwroot\wp-content\themes\inceptua\nectar\helpers\media.php on line 380

The Role of Pharmaceutical Manufacturers

What’s driving demand for unlicensed medicines in non-launch or non-com-mercialised markets? And what are the challenges for the pharmaceutical manufacturer of not actively engaging in providing access?

Irrespective of the manufacturers stance, demand will still exist in unlicensed markets. Healthcare professionals and patients will look to source the drug elsewhere. Without a corporate solution in place, allowing controlled access, what are the risks being taken by the manufacturer?